Welcome to the UPF Digital Repository

Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic

Show simple item record

dc.contributor.author Grau Cerrato, Santiago
dc.contributor.author Echeverría Esnal, Daniel
dc.contributor.author Gómez-Zorrilla, Silvia
dc.contributor.author Navarrete Rouco, Maria Eugenia
dc.contributor.author Masclans Enviz, Joan Ramon
dc.contributor.author Espona, Mercè
dc.contributor.author Gracia Arnillas, María Pilar
dc.contributor.author Duran Jordà, Xavier, 1974-
dc.contributor.author Comas Serrano, Mercè
dc.contributor.author Horcajada Gallego, Juan Pablo
dc.contributor.author Ferrández, Olivia
dc.date.accessioned 2021-06-25T07:24:04Z
dc.date.available 2021-06-25T07:24:04Z
dc.date.issued 2021
dc.identifier.citation Grau S, Echeverria-Esnal D, Gómez-Zorrilla S, Navarrete-Rouco ME, Masclans JR, Espona M, Gracia-Arnillas MP, Duran X, Comas M, Horcajada JP, Ferrández O. Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic. Antibiotics (Basel). 2021;10(2):132. DOI: 10.3390/antibiotics10020132
dc.identifier.issn 2079-6382
dc.identifier.uri http://hdl.handle.net/10230/47975
dc.description.abstract Background: The first wave of COVID-19 pandemic may have significantly impacted antimicrobial consumption in hospitals. The objective of this study was to assess the evolution of antimicrobial consumption during this period. Methods: A retrospective quasi-experimental before-after study was conducted in a Spanish tertiary care hospital. The study compared two periods: pre-pandemic, from January 2018 to February 2020, and during the COVID-19 pandemic from March to June 2020. Antimicrobial consumption was analyzed monthly as defined daily doses (DDD)/100 bed-days and overall hospital and ICU consumption were evaluated. Results: An increase in the hospital consumption was noticed. Although only ceftaroline achieved statistical significance (p = 0.014), a rise was observed in most of the studied antimicrobials. A clear temporal pattern was detected. While an increase in ceftriaxone and azithromycin was observed during March, an increment in the consumption of daptomycin, carbapenems, linezolid, ceftaroline, novel cephalosporin/β-lactamase inhibitors or triazoles during April-May was noticed. In the ICU, these findings were more evident, namely ceftriaxone (p = 0.029), carbapenems (p = 0.002), daptomycin (p = 0.002), azithromycin (p = 0.030), and linezolid (p = 0.011) but followed a similar temporal pattern. Conclusion: An increase in the antimicrobial consumption during the first wave of COVID-19 pandemic was noticed, especially in the ICU. Availability of updated protocols and antimicrobial stewardship programs are essential to optimize these outcomes.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartof Antibiotics (Basel). 2021;10(2):132
dc.rights © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/antibiotics10020132
dc.subject.keyword COVID-19
dc.subject.keyword Antibiotic consumption
dc.subject.keyword Antimicrobial resistance
dc.subject.keyword Antimicrobial stewardship
dc.subject.keyword Defined daily doses (DDD)
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking